Star Imaging

Why is Star Imaging and Path Lab Ltd falling/rising?

As of 17-Jul, Star Imaging and Path Lab Ltd's stock price is rising to Rs 97.68, showing a 2.3% increase due to strong relative performance, a trend reversal after declines, and positive investor sentiment reflected in increased trading volumes.

As of 17-Jul, Star Imaging and Path Lab Ltd's stock price is rising, currently at Rs 97.68, reflecting a change of Rs 2.2 or 2.3% increase. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.24% today, indicating strong relative performance. Additionally, there has been a trend reversal as the stock gained after three consecutive days of decline, suggesting renewed investor interest. <BR><BR>The stock also reached an intraday high of Rs 97.72, which is a 2.35% increase, demonstrating positive momentum. Furthermore, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish sign. <BR><BR>Investor participation has increased, with delivery volume on 16 July rising by 35.14% compared to the 5-day average, indicating growing confidence among investors. Overall, these factors contribute to the stock's rising price, reflecting a positive sentiment in the market for Star Imaging and Path Lab Ltd.

Which are the latest news on Star Imaging?

What does Star Imaging do?

Star Imaging and Path Lab Ltd is a micro-cap healthcare services company with a market cap of INR 143 Cr. It has a P/E ratio of 8.00, a negative debt-equity ratio of -0.27, and a return on equity of 16.65%.

Overview:<BR>Star Imaging and Path Lab Ltd operates in the healthcare services industry and is classified as a micro-cap company.<BR><BR>History:<BR>The incorporation year and any status changes are not provided. There are no sales and profit reports available for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 143 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.27<BR>Return on Equity: 16.65%<BR>Price-to-Book: 1.23<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Star Imaging?

Star Imaging's peers include Nureca, Jeevan Scientific, Bilcare, Aspira Pathlab, Choksi Laborator, Aakaar Medical, and QMS Medical. Star Imaging shows excellent management risk and growth, while Jeevan Scientific has the highest 1-year return at 95.63%, and Bilcare has the lowest at -24.68%.

Peers: The peers of Star Imaging are Nureca, Jeevan Scienti., Bilcare, Aspira Pathlab, Choksi Laborator, Aakaar Medical, and QMS Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, while Good management risk is found at Aakaar Medical. Below Average management risk is present at Nureca, Jeevan Scienti., Bilcare, Aspira Pathlab, Choksi Laborator, and the rest. Growth is Excellent at Star Imaging, Good at Aakaar Medical and Choksi Laborator, and Below Average at Nureca, Jeevan Scienti., Bilcare, Aspira Pathlab, and the rest. Capital Structure is Excellent at Star Imaging and Good at Aakaar Medical, while Average is found at Jeevan Scienti. and Aspira Pathlab, and Below Average at Nureca, Bilcare, Choksi Laborator, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jeevan Scienti. at 95.63%, while Bilcare has the lowest at -24.68%. Star Imaging's 1-year return is not available for comparison. Additionally, Nureca, Bilcare, and Choksi Laborator have negative six-month returns.

Is Star Imaging overvalued or undervalued?

As of December 3, 2025, Star Imaging is considered overvalued with a valuation grade of expensive, a PE ratio of 13.80, and strong returns on capital, despite a recent stock price decline and better valuations compared to peers like Max Healthcare and Apollo Hospitals.

As of 3 December 2025, Star Imaging's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 13.80, an EV to EBITDA of 8.67, and a ROE of 33.81%. In comparison to peers, Max Healthcare has a significantly higher PE ratio of 74.7, while Apollo Hospitals is at 61.84, highlighting that Star Imaging's valuation is more reasonable yet still on the higher side.<BR><BR>Despite the recent decline in stock price, with a 1-month return of -14.81% compared to a Sensex return of 1.34%, the company's strong ROCE of 31.55% and a PEG ratio of 0.00 suggest that it is generating substantial returns on capital. However, given the overall market conditions and peer comparisons, Star Imaging remains overvalued in its current state.

How has been the historical performance of Star Imaging?

Star Imaging has shown significant growth in shareholder's funds and total assets over the past four years, with shareholder's funds increasing to 47.15 Cr and total assets to 98.16 Cr by March 2025. Profit before tax improved to 21.00 Cr, although cash flow from operating activities turned negative, indicating potential cash generation challenges.

Answer:<BR>The historical performance of Star Imaging shows a significant increase in shareholder's funds and total assets over the past four years, with no standalone results declared. As of March 2025, shareholder's funds reached 47.15 Cr, up from 31.35 Cr in March 2024, and total assets also increased to 98.16 Cr from 81.64 Cr in the previous year. The company has seen a rise in total reserves, which grew to 33.65 Cr in March 2025 from 29.85 Cr in March 2024. Long-term borrowings decreased slightly to 14.87 Cr in March 2025 from 15.71 Cr in March 2024, while short-term borrowings increased to 17.86 Cr from 14.93 Cr in the same period. The profit before tax improved to 21.00 Cr in March 2025, compared to 16.00 Cr in March 2024, indicating a positive trend in profitability.<BR><BR>Breakdown:<BR>Star Imaging's financial metrics reflect a positive trajectory in its consolidated balance sheet and cash flow results. The company's shareholder's funds have shown a robust increase, rising from 18.36 Cr in March 2022 to 47.15 Cr in March 2025, while total assets have also grown significantly from 58.34 Cr to 98.16 Cr over the same period. Total reserves increased notably, indicating a strengthening financial position. Despite a slight decrease in long-term borrowings, short-term borrowings have risen, suggesting a shift in financing strategy. Profit before tax has improved markedly, moving from 0.00 Cr in March 2023 to 21.00 Cr in March 2025, showcasing enhanced operational performance. However, cash flow from operating activities turned negative in March 2025, indicating challenges in cash generation despite the overall growth in profitability.